International Drug Control Policy: Background and U.S. Responses (CRS Report for Congress)
Premium Purchase PDF for $24.95 (42 pages)
add to cart or
subscribe for unlimited access
Pro Premium subscribers have free access to our full library of CRS reports.
Subscribe today, or
request a demo to learn more.
Release Date |
Revised March 19, 2015 |
Report Number |
RL34543 |
Report Type |
Report |
Authors |
Liana Sun Wyler, Specialist in International Crime and Narcotics |
Source Agency |
Congressional Research Service |
Older Revisions |
-
Premium Revised March 16, 2015 (42 pages, $24.95)
add
-
Premium Revised Aug. 13, 2013 (47 pages, $24.95)
add
-
Premium Revised Jan. 14, 2013 (43 pages, $24.95)
add
-
Premium Revised Oct. 16, 2012 (42 pages, $24.95)
add
-
Premium Revised March 21, 2011 (52 pages, $24.95)
add
-
Premium Revised March 8, 2010 (46 pages, $24.95)
add
-
Premium Revised Aug. 24, 2009 (39 pages, $24.95)
add
-
Premium Revised Feb. 9, 2009 (37 pages, $24.95)
add
-
Premium Revised Aug. 28, 2008 (43 pages, $24.95)
add
-
Premium June 23, 2008 (42 pages, $24.95)
add
|
Summary:
The global illegal drug trade represents a multi-dimensional challenge that has implications for
U.S. national interests as well as the international community. Common illegal drugs trafficked
internationally include cocaine, heroin, and methamphetamine. According to the U.S. intelligence
community, international drug trafficking can undermine political and regional stability and
bolster the role and capabilities of transnational criminal organizations in the drug trade. Key
regions of concern include Latin America and Afghanistan, which are focal points in U.S. efforts
to combat the production and transit of cocaine and heroin, respectively. Drug use and addiction
have the potential to negatively affect the social fabric of communities, hinder economic
development, and place an additional burden on national public health infrastructures.
International Policy Framework and Debate
International efforts to combat drug trafficking are based on a long-standing and robust set of
multilateral commitments, to which the United States has committed. U.S. involvement in
international drug control rests on the central premise that helping foreign governments to combat
illicit drugs abroad will ultimately curb availability and use in the United States. To this end, the
current Administration maintains the goal of reducing and eliminating the international flow of
illegal drugs into the United States through international cooperation to disrupt the drug trade,
interdiction efforts, and support for demand reduction.
Despite multilateral commitments to curb the supply of illicit drugs, tensions appear at times
between U.S. foreign drug policy and approaches advocated by independent observers and other
members of the international community. In recent years, an increasing number of international
advocates, including several former and sitting heads of state, have begun to call for a
reevaluation of current prohibitionist-oriented international drug policies. Alternatives to the
existing international drug control regime may include legalizing or decriminalizing certain
drugs. Debates may also focus on shifting priorities and resources among various approaches to
counternarcotics, including supply and demand reduction; the distribution of domestic and
international drug control funding; and the relative balance of civilian, law enforcement, and
military roles in anti-drug efforts.
U.S. Counternarcotics Initiatives and Foreign Policy Options
Several key U.S. strategies and initiatives outline the foundation of U.S. counternarcotics efforts
internationally, including the U.S. National Drug Control Strategy and International Narcotics
Control Strategy Report (INCSR), both of which are updated annually and congressionally
mandated. Other major country and regional initiatives include the (1) Mérida Initiative and
Strategy in Mexico; (2) Central American Citizen Security Partnership; (3) Caribbean Basin
Security Initiative (CBSI); (4) U.S.-Colombia Strategic Development Initiative (CSDI); (5) U.S.
Counternarcotics Strategy for Afghanistan; and (6) West Africa Cooperative Security Initiative
(WACSI).
Located within the Executive Office of the President, the Office of National Drug Control Policy
(ONDCP) establishes U.S. counterdrug policies and goals, and coordinates the federal budget to
combat drugs both domestically and internationally. Within the U.S. government, multiple
civilian, military, law enforcement, and intelligence entities contribute to international drug
control policy, including the U.S. Department of State, U.S. Agency for International Development, U.S. Department of Defense, U.S. Department of Justice, U.S. Department of
Homeland Security, U.S. Department of the Treasury, and the Central Intelligence Agency.
As an issue of international policy concern for more than a century, and as a subject of longstanding
U.S. and multilateral policy commitment, U.S. counterdrug efforts have expanded to
include a broad array of tools to attack the international drug trade, such as the following:
• reducing drug production at the source,
• combating drugs in transit,
• dismantling international illicit drug networks,
• reducing and preventing drug demand abroad, and
• creating incentives for international cooperation on drug control.
Congress has been involved in all aspects of U.S. international drug control policy, regularly
appropriating funds for counterdrug initiatives, as well as conducting oversight activities on
federal counterdrug programs and the scope of agency authorities and other counterdrug policies.
For FY2016, the Administration has requested from Congress approximately $27.6 billion for all
federal drug control programs, of which $1.6 billion is requested for international programs,
including civilian and military U.S. foreign assistance. An additional $3.9 billion is requested for
interdiction programs related to intercepting and disrupting foreign drug shipments en route to the
United States.